On November 18, 2024, the Hong Kong stock market opened higher. The Hang Seng Index (HSI) rose by 0.87%, the Hang Seng China Enterprises Index (HSCEI) increased by 0.92%, the Hang Seng Tech Index (HSTECH) climbed by 1.19%, and the Hang Seng China-Affiliated Corporations Index (HSCCI) went up by 0.58%.

In terms of industry sectors, the Hong Kong education sector saw a significant increase, with New Oriental-S rising by 3.18%. The SaaS concept stocks also performed well, with Kingsoft up by 2.61%. The insurance sector showed strong performance, with Ping An increasing by 2.41%.

JD-SW surged by 4.07%. The company has been performing well in the market, attracting investor attention.

BABA-W fell by 0.40%. Alibaba Group has mandated investment banks to work on a multi-tranche dollar and offshore Chinese yuan bond deals. The company is considering issuing bonds with different maturities, including 5.5-year, 10.5-year, and 30-year dollar bonds, as well as 3.5-year, 5-year, 10-year, and 20-year offshore yuan bonds. The funds raised will be used for general corporate purposes, including debt repayment and funding share repurchases.

CITIC SEC saw a slight increase of 0.23%. The China Securities Regulatory Commission (CSRC) issued market value management guidelines, which are expected to benefit the coal sector. CITIC Securities believes that the disclosure of these guidelines will support the dividend style, and the coal sector, being a major index component, is likely to benefit more significantly.

IMMUNEONCO-B dropped by 3.81%. The company announced that the Ib/IIa phase clinical trial of IMM0306 combined with lenalidomide for the treatment of chronic lymphoma had recruited a total of 27 evaluable patients as of October 26. IMM0306 is a bispecific molecule targeting CD47 and CD20, the first of its kind to enter the clinical stage globally. It can bind to both CD47 and CD20 expressed on malignant B cells, improving treatment efficacy.